RIGL
What one share of Rigel Pharmaceuticals holds
Pharmaceutical Preparations
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.
Rigel Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.15 |
|---|---|
| Profit | $16.45 |
| Cash and investments | $3.26 |
| Debt | $2.14 |
| Book value | $22.77 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.16 | −$7.33 | $0.09 | −$8.13 | — | — |
| 2017 | $0.35 | −$6.17 | $0.01 | −$6.15 | — | — |
| 2018 | $2.77 | −$4.39 | $0.07 | −$3.73 | — | — |
| 2019 | $3.54 | −$4.00 | $0.09 | −$2.57 | — | — |
| 2020 | $6.44 | −$1.76 | $0.07 | −$3.17 | — | — |
| 2021 | $8.75 | −$1.10 | $0.04 | $0.31 | — | — |
| 2022 | $7.05 | −$3.44 | $0.03 | −$4.35 | — | — |
| 2023 | $6.72 | −$1.44 | — | −$0.33 | — | — |
| 2024 | $10.14 | $0.99 | — | $1.78 | — | — |
| 2025 | $15.62 | $19.48 | — | $4.02 | — | $21.38 |